It has recently been suggested that metabolomics studies before and after the onset of SMA in patients can provide valuable information about the direct or indirect effects of SMN deficiency on metabolic abnormalities. This evidence concerns the gene SMN1 and hyperinsulinemic hypoglycemia, familial, 4.